How We Deliver
Achieving Leadership in AAV Manufacturing
We are committed to adeno-associated virus (AAV) and to the patients that ultimately benefit from our work. Delivering on this value is important to the entire Oxford Biomedica team.
Everything we do and how we do it comes from our commitment to our partners and their patients.
Emphasizing Continuous Innovation
To gain and maintain leadership in the AAV development field, Oxford Biomedica is passionate about continuous learning and innovation.
Each member of the team is constantly looking for creative ways to improve and innovate every process.
We are continually learning and expanding our knowledge so that we never stop innovating.
This is our approach to AAV manufacturing.
We know this is the only way to ensure we are delivering the highest product quality and efficacy to your patients– and to ensure we’re always ready for the next challenge.
We’re always ready for the next challenge.
We have made improvements to our plasmid-transfection* process to increase the bioreactor titer yields 10X above industry average.
Oxford Biomedica is continuing to innovate on The Full Solution™ suite of services, with plans to incorporate novel methods, such as optimized plasmid design and improved separation technology,* to increase efficiencies that facilitate even greater vector genome productivity.
Those are just two examples of how we consistently strive to stay ahead of the learning curve.
Our Approach Is Making a Difference
Starting with The Full Solution™ suite of services through
all the way to clinical use and full commercialization—
Combined with our commitment to deliver
- cross-functional teamwork
the consistent Oxford Biomedica approach is to identify what works best for each individual product and then execute to your expectations.